Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management

INCLUSION CRITERIA * Men and women over the age of 18 * Patient treated in the context of a tumor pathology during which he received treatment with bisphosphonates, Denosumab or anti-angiogenics, and/or, very often, switch of treatment or combination. Current treatment or mention of treatment in patient history * MRONJ stage II certified clinically and radiologically. Also in the maxilla, stage II MRONJ without bucco-sinus communication after excision of the necrotic bone. Similarly, if a tooth with antral roots must be extracted and creates a bucco-sinus communication, if a MRONJ results, it will be stage II * Patients with stage II MRONJ of childbearing age with current contraception or patients already postmenopausal * Signature of the informed consent to participate indicating that the subject has understood the purpose and the procedures required by the study, that he agrees to participate in the study as well as to comply with the requirements and restrictions inherent in this study * Affiliation to a French social security scheme or beneficiary of such a scheme NON-INCLUSION CRITERIA * Life expectancy of less than 6 months assessed by oncologists * Existence of an evolving cervico-facial neoplasia or an evolving oral neoplastic process informed by oncologists * History of oral and/or cervico-facial radiotherapy * Allergy to one of these two antibiotics: amoxicillin-clavulanic acid or clindamycin-metronidazole combination * Patient contraindicated for surgery due to …